Eprosartan
(Redirected from Teveten)
 | |
| Clinical data | |
|---|---|
| Trade names | Teveten |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601237 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 15% (Eprosartan mesylate) |
| Metabolism | not metabolized |
| Elimination half-life | 5 to 9 hours |
| Excretion | Kidney 10%, bile duct 90% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H24N2O4S |
| Molar mass | 424.52 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Eprosartan, sold under the brand name Teveten among others, is an angiotensin II receptor antagonist used for the treatment of high blood pressure.[1]
Eprosartan is sometimes paired with hydrochlorothiazide.[2]
As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.[3]
History
[edit]The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.[4]
References
[edit]- ^ "Eprosartan mesylate- eprosartan mesylate tablet, film coated". DailyMed. Retrieved 7 June 2023.
- ^ "Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet". DailyMed. 3 January 2012. Retrieved 7 June 2023.
- ^ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061. S2CID 13063704.
- ^ Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [1], accessed 29 January 2015.
